Hi everyone
As you might know, two drugs for secondary breast cancer are currently being assessed by the National Institute of Health and Care Excellence (NICE):
- Fulvestrant (brand name Faslodex) for treatment of women with untreated, HR positive, secondary breast cancer.
- Ribococlib (brand name Kisqali) for treatment of postmenopausal women with untreated, HER2 negative, HR positive secondary breast cancer.
We will be submitting a response to NICE as part of the assessment process, and would like to hear your views on the impact having access to this drug could have, both for people with secondary breast cancer and those around them.
Feedback on the following areas would be especially helpful:
- Concerns you have about current NHS treatments in England (if any)
- The benefits of either Fulvestrant or Ribociclib (e.g. impact on physical symptoms, increased quality of life)
- Any disadvantages of either Fulvestrant or Ribociclib (e.g. side effects, travelling to/from hospital for treatments)
As a result of their assessment, NICE will make recommendations about whether or not these drugs should be routinely available in England, so your feedback will help us make sure the voice of people with secondary breast cancer is heard.
Please email campaigns@breastcancercare.org.uk to share your views and experiences, by Wednesday 22 March.
If you have any questions about this, feel free to email me on the above, or comment on this thread.
All the best
Emma, the Policy & Campaigns team at Breast Cancer Care